



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 18 Oct 2021 (#34)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notices

[NOT-OD-22-001](#) NIH Implementation of the Revised Common Rule Provision Regarding Public Health Surveillance Activities Deemed Not to Be Research. The National Institutes of Health (NIH) is informing the research community of its implementation of a provision in the 2018 Requirements for the Federal Policy for the Protection of Human Subjects (“the revised Common Rule”) under which public health surveillance activities may be deemed not to be research for the purposes of the regulation (45 CFR 46.102(l)(2)).

## Notices of Special Interest

[NOT-HL-23-002](#): Notice of Special Interest (NOSI): Promoting research to understand vascular contributions to cognitive impairment and dementia (VCID). The purpose of this Notice is to inform potential applicants about an area of special interest to NHLBI, NINDS and NIA in research to understand mechanisms of vascular contributions to cognitive impairment and dementia (VCID) and to develop new approaches for the treatment of VCID. This notice applies to application receipt dates on or after February 5, 2022 and subsequent receipt dates through May 8, 2025. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-183](#) NIH Research Project Grant (Parent R01 Clinical Trial Required)

## Funding Opportunity Announcements (FOA)

### 1. Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-21-341](#)

**Type:** R21

**Application Due Date:** June 07, 2022; October 07, 2022; June 07, 2023; October 09, 2023; June 07, 2024; October 08, 2024. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in a single year. The maximum project period is 2 years.

### 2. Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-039](#)

**Type:** R01

**Application Due Date:** February 05, 2022; June 05, 2022; October 05, 2022 through to October 05, 2024. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. **Companion funding:** [PAR-22-038](#), [R21](#) Exploratory/Developmental Grants.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request \$500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

### 3. Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimer's Disease and Related Dementias (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-048](#)

**Type:** R01

**Application Due Date:** March 11, 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) supports mechanistic and early translational research focused on a more rigorous in-depth examination of the potential interactions of environmental toxins with genetic and non-genetic molecular targets known to influence Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). It is expected that these studies will address the clinical relevance of these exposures on disease initiation, progression, or modification. Anticipated outcomes include an improved understanding of neurological mechanisms of chemical toxicities related to AD/ADRD, more evidence-based potential biomarkers of exposure and toxicity for those most at risk, as well as more data to support causality and potential approaches for mitigation. The scope of research includes mechanistic studies on the modification of known AD/ADRD targets by neurotoxins of concern, and conversely, whether known targets for these neurotoxins play a role in etiologies of AD/ADRD. The development and validation of neuropathological, neurophysiological and neurobehavioral animal models that simulate potential toxin exposures in humans is another example of supported studies. Preclinical studies of interactions of environmental toxicant with AD/ADRD in pilot human subject studies (that do not meet the NIH definition of clinical trial) are appropriate for this FOA. Interdisciplinary collaboration is required to address the various fields of study related to this research, e.g., neuroscience, aging, and environmental health sciences.

**Budget:** NINDS and NIA intend to commit an estimated total of \$3,750,000 per year to fund 5 awards. Application budgets are limited to no more than \$500,000 in direct costs per year and need to reflect the actual needs of the proposed project. The maximum project period should not exceed 5 years.

#### 4. Advancing Group A Streptococcus Vaccine Discovery (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-21-070](#)

**Type:** R01

**Application Due Date:** February 18, 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support discovery and design of novel Group A Streptococcus (GAS) vaccine candidates and their advancement into preclinical evaluation for broad protection against GAS infections.

**Budget:** NIAID intends to commit \$3 million in FY 2023 to fund 3-5 awards. Application budgets are limited to less than \$500,000 in direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105